申请人:——
公开号:US20030096705A1
公开(公告)日:2003-05-22
The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.
本发明涉及化合物、包含该化合物的药物组合物、使用该化合物和组合物的用途、使用该化合物和组合物的治疗方法,以及制备该化合物的过程。具体而言,本发明涉及新型化合物,这些化合物是 MCP-1 功能拮抗剂,可用于预防或治疗慢性或急性炎症性或自身免疫性疾病,特别是那些与淋巴细胞或单核细胞异常积聚有关的疾病,如关节炎、哮喘、动脉粥样硬化、糖尿病肾病、炎性肠病、克罗恩病、多发性硬化、肾炎、胰腺炎、肺纤维化、银屑病、再狭窄和移植排斥反应。更具体地,本发明涉及包含这些化合物的药物组合物以及使用这些化合物和组合物预防或治疗这些疾病。